NASDAQ:VXRT - Vaxart Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 149.17 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.02
▲ +0.1 (1.69%)
1 month | 3 months | 12 months
Get New Vaxart Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VXRT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VXRT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$15.00
▲ +149.17% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Vaxart in the last 3 months. The average price target is $15.00, with a high forecast of $17.00 and a low forecast of $13.00. The average price target represents a 149.17% upside from the last price of $6.02.
Buy
The current consensus among 2 polled investment analysts is to buy stock in Vaxart.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/12/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/11/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2021B. RileyReiterated RatingBuy$16.00 ➝ $13.00High
i
12/3/2020B. RileyReiterated RatingBuy$22.00High
i
Rating by Mayank Mamtani at B. Riley
11/18/2020B. RileyLower Price TargetBuy$22.00 ➝ $16.00Low
i
Rating by Mayank Mamtani at B. Riley
8/12/2020HC WainwrightBoost Price TargetBuy$7.00 ➝ $17.00High
i
Rating by Vernon Bernardino at HC Wainwright
8/7/2020B. RileyReiterated RatingBuy$22.00Low
i
Rating by Mayank Mamtani at B. Riley
7/12/2020B. RileyInitiated CoverageBuy$22.00High
i
Rating by Mayank Mamtani at B. Riley
5/13/2020HC WainwrightReiterated RatingBuy$7.00High
i
Rating by Vernon Bernardino at HC Wainwright
4/30/2020HC WainwrightReiterated RatingBuy$3.00 ➝ $7.00High
i
Rating by Vernon Bernardino at HC Wainwright
4/23/2020HC WainwrightReiterated RatingBuy$3.00Medium
i
Rating by Vernon Bernardino at HC Wainwright
3/19/2020HC WainwrightReiterated RatingBuy$3.00High
i
Rating by Vernon Bernardino at HC Wainwright
11/18/2019HC WainwrightReiterated RatingBuy$2.00High
i
Rating by Vernon Bernardino at HC Wainwright
8/21/2019HC WainwrightSet Price TargetBuy$2.00High
i
Rating by Vernon Bernardino at HC Wainwright
8/15/2019Brookline Capital ManagementInitiated CoverageBuy$6.00Low
i
Rating by K. Raja at Brookline Capital Management
6/27/2019HC WainwrightInitiated CoverageBuy$2.00Low
i
Rating by V. Bernardino at HC Wainwright
11/6/2017HC WainwrightReiterated RatingHoldN/A
i
10/31/2017HC WainwrightReiterated RatingHoldN/A
i
2/15/2017HC WainwrightDowngradeBuy ➝ NeutralN/A
i
Rating by E. Arce at HC Wainwright
2/14/2017LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralN/A
i
2/6/2017HC WainwrightReiterated RatingBuy$5.00N/A
i
11/7/2016(FBRC)Reiterated RatingBuyN/A
i
9/21/2016LADENBURG THALM/SH SHInitiated CoverageBuyN/A
i
9/20/2016HC WainwrightReiterated RatingBuyN/A
i
7/13/2016HC WainwrightInitiated CoverageBuy$5.00N/A
i
Rating by E. Arce at HC Wainwright
5/31/2016(FBRC)Reiterated RatingOutperformN/A
i
3/18/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Christopher James at (FBRC)
(Data available from 3/6/2016 forward)
Vaxart logo
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. Vaxart, Inc. is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $6.02
$5.28
$6.17

50 Day Range

MA: $8.50
$5.92
$23.33

52 Week Range

Now: $6.02
$1.08
$24.90

Volume

9,111,593 shs

Average Volume

18,655,768 shs

Market Capitalization

$708.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vaxart?

The following equities research analysts have issued reports on Vaxart in the last year: B. Riley, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for VXRT.

What is the current price target for Vaxart?

2 Wall Street analysts have set twelve-month price targets for Vaxart in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 163.6%. HC Wainwright has the highest price target set, predicting VXRT will reach $17.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $13.00 for Vaxart in the next year.
View the latest price targets for VXRT.

What is the current consensus analyst rating for Vaxart?

Vaxart currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VXRT will outperform the market and that investors should add to their positions of Vaxart.
View the latest ratings for VXRT.

What other companies compete with Vaxart?

How do I contact Vaxart's investor relations team?

Vaxart's physical mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company's listed phone number is (650) 550-3500 and its investor relations email address is [email protected] The official website for Vaxart is www.vaxart.com.